Abstract
Presentation Description :
This presentation will provide information on a phase II pilot, multicenter, placebo-controlled clinical trial (NCT02613572) evaluating the re-purposing of alpha lipoic acid as a treatment for the geographic atrophy of age-related macular degeneration (AMD). Background will be provided on alpha lipoic acid, a nutraceutical that is a potent antioxidant and iron-chelator. Animal model data relevant to AMD will be discussed. The trial design will be covered in detail. There are no patient treatment recommendations in this presentation.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.